OKN-007

DRUG4 trials

Conditions

AstrocytomaBrain GlioblastomaDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantGlioblastomaOligodendrogliomaRecurrent Malignant Glioma

Phase 1

Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

NCT01672463

Oblato, Inc.Recurrent Malignant Glioma

Start: 2012-12-31End: 2023-10-31Target: 31Updated: 2023-03-29

Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants

WithdrawnNCT03649464

Oblato, Inc.Astrocytoma, Glioblastoma, Oligodendroglioma

Start: 2022-08-31End: 2025-08-31Updated: 2022-10-07

Phase 2

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

CompletedNCT04388475

Oblato, Inc.Brain Glioblastoma, Recurrent Malignant Glioma

Start: 2020-06-12End: 2025-03-05Updated: 2025-08-12

Unknown Phase

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

NCT05518838

Oblato, Inc.Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant

Updated: 2024-11-08

Related Papers

Abstract CT201: Phase 2 clinical trial of OKN-007 in recurrent malignant glioma

Cancer Research2024-04-052 citations

CTNI-39. PHASE 1B CLINICAL TRIAL OF OKN-007 IN RECURRENT MALIGNANT GLIOMA

Neuro-Oncology2020-11-01

Phase Ib clinical trial of OKN-007 in recurrent malignant glioma.

Journal of Clinical Oncology2020-05-207 citations